Alkermes receives orphan drug status for alixorexton in U.S. and Europe
Go back to Alkermes receives orphan drug status for alixorexton in U.S. and Europe| ALKERMES (NASDAQ: ALKS) | Delayed: 47.78 +1.76 (3.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.02 | 52 Week High | $80.71 | |||
| Open | $46.00 | 52 Week Low | $27.14 | |||
| Day High | $48.07 | P/E | 367.54 | |||
| Day Low | $45.47 | EPS | $0.13 | |||
| Volume | 933,841 | |||||
